Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model

BACKGROUND: Approximately 7.3 million people with type 1 or type 2 diabetes (T1D/T2D) are treated with insulin, placing them at higher risk of severe hypoglycemia (SH). SH requires assistance of another individual and often necessitates the prompt administration of intravenous glucose, injectable gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinahara, Jordan, Weinzimer, Stuart A, Bromley, Emilie R, Goss, Thomas F, Kendall, David M, Hammer, Mette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373001/
https://www.ncbi.nlm.nih.gov/pubmed/35332789
http://dx.doi.org/10.18553/jmcp.2022.28.4.461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373001/
https://www.ncbi.nlm.nih.gov/pubmed/35332789
http://dx.doi.org/10.18553/jmcp.2022.28.4.461

Ejemplares similares